Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Remimazolam Tosylate Sedation Dosing in ERCP Patients of Different Ages
ChiCTR2200060357Phase 4Recruiting
- Sponsor
- The First Affiliated Hospital of University of Science and Technology of China
- Start
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of remimazolam in choledocholithiasis, suppurative cholangitis (ASC) and biliary stricture (4 arms), sponsored by The First Affiliated Hospital of University of Science and Technology of China. Primary endpoints: Modified Observer’s Assessment of Alertness/Sedation (MOAA/S) and Bispectral index (BIS). Started May 2022; status: recruiting.
02
Drugs
remimazolam
03
Conditions
choledocholithiasissuppurative cholangitis (ASC)biliary stricture
Beyond the preview
Go deeper on ChiCTR2200060357.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200060357.